Your browser doesn't support javascript.
loading
Rationale, design and methodology of APPROACH-IS II: International study of patient-reported outcomes and frailty phenotyping in adults with congenital heart disease.
Van Bulck, Liesbet; Kovacs, Adrienne H; Goossens, Eva; Luyckx, Koen; Zaidi, Ali; Wang, Jou-Kou; Yadeta, Dejuma; Windram, Jonathan; Van De Bruaene, Alexander; Thomet, Corina; Thambo, Jean-Benoît; Taunton, Marshall; Sasikumar, Navaneetha; Sandberg, Camilla; Saidi, Arwa; Rutz, Tobias; Ortiz, Lucia; Mwita, Julius Chacha; Moon, Ju Ryoung; Menahem, Samuel; Mattsson, Eva; Mandalenakis, Zacharias; Mahadevan, Vaikom S; Lykkeberg, Birgitte; Leye, Mohamed; Leong, Ming Chern; Ladouceur, Magalie; Ladak, Laila Akbar; Kim, Yuli; Khairy, Paul; Kaneva, Anna; Johansson, Bengt; Jackson, Jamie L; Giannakoulas, George; Gabriel, Harald; Fernandes, Susan M; Enomoto, Junko; Demir, Fatma; de Hosson, Michèle; Constantine, Andrew; Coats, Louise; Christersson, Christina; Cedars, Ari; Caruana, Maryanne; Callus, Edward; Brainard, Sarah; Bouchardy, Judith; Boer, Anna; Baraona Reyes, Fernando; Areias, Maria Emília.
Afiliação
  • Van Bulck L; KU Leuven - University of Leuven, Leuven, Belgium; Research Foundation Flanders (FWO), Brussels, Belgium.
  • Kovacs AH; Oregon Health & Science University, Portland, OR, USA.
  • Goossens E; KU Leuven - University of Leuven, Leuven, Belgium; University of Antwerp, Antwerp, Belgium.
  • Luyckx K; KU Leuven - University of Leuven, Leuven, Belgium; UNIBS, University of the Free State, Bloemfontein, South Africa.
  • Zaidi A; Mount Sinai Heart, New York, NY, USA.
  • Wang JK; National Taiwan University Hospital, Taipei City, Taiwan.
  • Yadeta D; Addis Ababa University, Addis Ababa, Ethiopia.
  • Windram J; Mazankowski Alberta Heart Institute, Edmonton, Canada.
  • Van De Bruaene A; University Hospitals Leuven, Leuven, Belgium.
  • Thomet C; Inselspital, Bern University Hospital, University of Bern, Switzerland.
  • Thambo JB; Hôpital cardiologique Haut-Leveque, Bordeaux, France.
  • Taunton M; Oregon Health & Science University, Portland, OR, USA.
  • Sasikumar N; Amrita Institute of Medical Sciences, Kochi, Kerala, India.
  • Sandberg C; Umeå University, Umeå, Sweden.
  • Saidi A; University of Florida Health, Gainesville, FL, USA.
  • Rutz T; Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Ortiz L; Hospital San Juan De Dios De La Plata, Buenos Aires, Argentina.
  • Mwita JC; University of Botswana and Princess Marina Hospital, Gaborone, Botswana.
  • Moon JR; Samsung Medical Center, Seoul, South Korea.
  • Menahem S; Monash University, Melbourne, Australia.
  • Mattsson E; Karolinska Institutet, Stockholm, Sweden.
  • Mandalenakis Z; Sahlgrenska University Hospital/Östra, Gothenburg, Sweden.
  • Mahadevan VS; University of California San Francisco (UCSF), San Francisco, CA, USA.
  • Lykkeberg B; Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Leye M; University of Thiés, Thiés, Senegal.
  • Leong MC; IJN (National Heart Institute), Kuala Lumpur, Malaysia.
  • Ladouceur M; Hôpital Européen Georges Pompidou, AP-HP Paris, France.
  • Ladak LA; Aga Khan University, Karachi, Pakistan.
  • Kim Y; Penn Medicine and Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Khairy P; Montreal Heart Institute, Université de Montréal, Montreal, Canada.
  • Kaneva A; National Heart Hospital, Sofia, Bulgaria.
  • Johansson B; Umeå University, Umeå, Sweden.
  • Jackson JL; Nationwide Children's Hospital, Columbus, OH, USA.
  • Giannakoulas G; AHEPA University Hospital, Aristotle University of Thessaloniki, Greece.
  • Gabriel H; Medical University of Vienna, Vienna, Austria.
  • Fernandes SM; Lucile Packard Children's Hospital and Stanford Health Care, Stanford, CA, USA.
  • Enomoto J; Chiba Cerebral and Cardiovascular Center, Chiba, Japan; Toyo University, Tokyo, Japan.
  • Demir F; Ege University Health Application and Research Center, Bornova/IZMIR, Turkey.
  • de Hosson M; Ghent University Hospital, Ghent, Belgium.
  • Constantine A; Royal Brompton Hospital, Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Coats L; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Christersson C; Uppsala University, Uppsala, Sweden.
  • Cedars A; University of Southwestern Medical Center, TX, Dallas, USA; Johns Hopkins Hospital, Baltimore, MD, USA.
  • Caruana M; Mater Dei Hospital, L-Imsida, Malta.
  • Callus E; IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; University of Milan, Milan, Italy.
  • Brainard S; Boston Children's Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bouchardy J; Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Hôpitaux Universitaires de Genève, Genève, Switzerland.
  • Boer A; University Medical Center Groningen, Groningen, the Netherlands.
  • Baraona Reyes F; Pontificia Universidad Católica de Chile and Instituto Nacional Del Torax, Santiago, Chile.
  • Areias ME; UnIC@RISE, University of Porto, Porto, Portugal; Centro Hospitalar Universitário de S. João, Porto, Portugal.
Int J Cardiol ; 363: 30-39, 2022 09 15.
Article em En | MEDLINE | ID: mdl-35780933
BACKGROUND: In recent years, patient-reported outcomes (PROs) have received increasing prominence in cardiovascular research and clinical care. An understanding of the variability and global experience of PROs in adults with congenital heart disease (CHD), however, is still lacking. Moreover, information on epidemiological characteristics and the frailty phenotype of older adults with CHD is minimal. The APPROACH-IS II study was established to address these knowledge gaps. This paper presents the design and methodology of APPROACH-IS II. METHODS/DESIGN: APPROACH-IS II is a cross-sectional global multicentric study that includes Part 1 (assessing PROs) and Part 2 (investigating the frailty phenotype of older adults). With 53 participating centers, located in 32 countries across six continents, the aim is to enroll 8000 patients with CHD. In Part 1, self-report surveys are used to collect data on PROs (e.g., quality of life, perceived health, depressive symptoms, autonomy support), and explanatory variables (e.g., social support, stigma, illness identity, empowerment). In Part 2, the cognitive functioning and frailty phenotype of older adults are measured using validated assessments. DISCUSSION: APPROACH-IS II will generate a rich dataset representing the international experience of individuals in adult CHD care. The results of this project will provide a global view of PROs and the frailty phenotype of adults with CHD and will thereby address important knowledge gaps. Undoubtedly, the project will contribute to the overarching aim of improving optimal living and care provision for adults with CHD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fragilidade / Cardiopatias Congênitas Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Cardiol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fragilidade / Cardiopatias Congênitas Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Cardiol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica